Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine.
Tara M BabuXiaoying ShenR Scott McClellandZijun WangStacy SelkeChloe WilkensKirsten A HaugeChristopher L McClurkanErin GoeckerKerry J LaingDavid M KoelleAlexander L GreningerMichel C NussenzweigDavid C MontefioriLawrence CoreyAnna WaldPublished in: Open forum infectious diseases (2024)
We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.
Keyphrases